Logo image of 1VKTX.MI

VIKING THERAPEUTICS INC (1VKTX.MI) Stock Fundamental Analysis

Europe - BIT:1VKTX - US92686J1060 - Common Stock

23.41 EUR
+1.65 (+7.58%)
Last: 10/2/2025, 7:00:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to 1VKTX. 1VKTX was compared to 73 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for 1VKTX as it has an excellent financial health rating, but there are worries on the profitability. 1VKTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year 1VKTX has reported negative net income.
1VKTX had a negative operating cash flow in the past year.
1VKTX had negative earnings in each of the past 5 years.
In the past 5 years 1VKTX always reported negative operating cash flow.
1VKTX.MI Yearly Net Income VS EBIT VS OCF VS FCF1VKTX.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

1VKTX has a Return On Assets (-20.72%) which is in line with its industry peers.
The Return On Equity of 1VKTX (-21.57%) is better than 67.12% of its industry peers.
Industry RankSector Rank
ROA -20.72%
ROE -21.57%
ROIC N/A
ROA(3y)-25.43%
ROA(5y)-23.56%
ROE(3y)-28.18%
ROE(5y)-25.59%
ROIC(3y)N/A
ROIC(5y)N/A
1VKTX.MI Yearly ROA, ROE, ROIC1VKTX.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for 1VKTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
1VKTX.MI Yearly Profit, Operating, Gross Margins1VKTX.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, 1VKTX has more shares outstanding
Compared to 5 years ago, 1VKTX has more shares outstanding
1VKTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
1VKTX.MI Yearly Shares Outstanding1VKTX.MI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
1VKTX.MI Yearly Total Debt VS Total Assets1VKTX.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 56.51 indicates that 1VKTX is not in any danger for bankruptcy at the moment.
1VKTX has a better Altman-Z score (56.51) than 100.00% of its industry peers.
1VKTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 56.51
ROIC/WACCN/A
WACCN/A
1VKTX.MI Yearly LT Debt VS Equity VS FCF1VKTX.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 25.86 indicates that 1VKTX has no problem at all paying its short term obligations.
The Current ratio of 1VKTX (25.86) is better than 98.63% of its industry peers.
A Quick Ratio of 25.86 indicates that 1VKTX has no problem at all paying its short term obligations.
The Quick ratio of 1VKTX (25.86) is better than 98.63% of its industry peers.
Industry RankSector Rank
Current Ratio 25.86
Quick Ratio 25.86
1VKTX.MI Yearly Current Assets VS Current Liabilites1VKTX.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for 1VKTX have decreased strongly by -62.77% in the last year.
EPS 1Y (TTM)-62.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-190%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 4.59% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-147.07%
EPS Next 2Y-78.61%
EPS Next 3Y-50.63%
EPS Next 5Y4.59%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
1VKTX.MI Yearly Revenue VS Estimates1VKTX.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
1VKTX.MI Yearly EPS VS Estimates1VKTX.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for 1VKTX. In the last year negative earnings were reported.
Also next year 1VKTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
1VKTX.MI Price Earnings VS Forward Price Earnings1VKTX.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
1VKTX.MI Per share data1VKTX.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

A cheap valuation may be justified as 1VKTX's earnings are expected to decrease with -50.63% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-78.61%
EPS Next 3Y-50.63%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for 1VKTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIKING THERAPEUTICS INC

BIT:1VKTX (10/2/2025, 7:00:00 PM)

23.41

+1.65 (+7.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-23 2025-07-23/amc
Earnings (Next)10-22 2025-10-22/amc
Inst Owners67.53%
Inst Owner ChangeN/A
Ins Owners2.15%
Ins Owner ChangeN/A
Market Cap2.63B
Analysts86.09
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-25.64%
Min EPS beat(2)-27.37%
Max EPS beat(2)-23.91%
EPS beat(4)1
Avg EPS beat(4)-12.66%
Min EPS beat(4)-27.37%
Max EPS beat(4)14.36%
EPS beat(8)4
Avg EPS beat(8)-1.83%
EPS beat(12)6
Avg EPS beat(12)-1.06%
EPS beat(16)8
Avg EPS beat(16)0.69%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)-1.02%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.98%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.88
P/tB 3.88
EV/EBITDA N/A
EPS(TTM)-1.3
EYN/A
EPS(NY)-2.72
Fwd EYN/A
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)-1.16
OCFYN/A
SpS0
BVpS6.03
TBVpS6.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.72%
ROE -21.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.43%
ROA(5y)-23.56%
ROE(3y)-28.18%
ROE(5y)-25.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 25.86
Quick Ratio 25.86
Altman-Z 56.51
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-62.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-190%
EPS Next Y-147.07%
EPS Next 2Y-78.61%
EPS Next 3Y-50.63%
EPS Next 5Y4.59%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-70.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-106.94%
EBIT Next 3Y-43.61%
EBIT Next 5Y-26.07%
FCF growth 1Y-152.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-152.08%
OCF growth 3YN/A
OCF growth 5YN/A